Twenty state attorneys general sued a group of generic drug companies Thursday, accusing them of conspiring to fix prices on an antibiotic and a diabetes medication.
The suit comes a day after price-fixing charges against former executives at one of the drugmakers were unsealed in a Justice Department antitrust probe.
The attorneys general, including New York’s Eric Schneiderman and Connecticut’s George Jepsen, alleged in a suit filed in Connecticut federal court that Heritage Pharmaceuticals; Aurobindo Pharma USA; Citron Pharma; Mayne Pharma; Mylan Pharmaceuticals; and Teva Pharmaceuticals USA, conspired to manipulate prices for doxycycline hyclate, an antibiotic, and glyburide, used in the treatment of diabetes.
On Wednesday, federal prosecutors unsealed charges against Heritage’s former chief executive and former president, alleging they conspired with competitors to fix prices and allocate customers for the same two drugs.
Heritage has said it fired those executives and is cooperating with the Justice Department.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ Antitrust Chief Gail Slater Assembles Veteran Team for Key Cases
Mar 16, 2025 by
CPI
UK Demands Access to Apple’s Encrypted Cloud Data, Spark Legal and Privacy Battle
Mar 16, 2025 by
CPI
Turkey Probes Netflix, Disney+, and Amazon Over Anti-Competitive Practices
Mar 16, 2025 by
CPI
Elon Musk and OpenAI Agree to Accelerate Trial Amidst Legal Battle Over AI’s For-Profit Shift
Mar 16, 2025 by
CPI
AI in Markets: A Double-Edged Sword for Competition, Says CCI Chief
Mar 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li